Aurobindo Pharma Limited

BSE:524804 Stock Report

Market Cap: ₹680.6b

Aurobindo Pharma Valuation

Is 524804 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524804 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.40k
Fair Value
16.4% undervalued intrinsic discount
28
Number of Analysts

Below Fair Value: 524804 (₹1171.75) is trading below our estimate of fair value (₹1400.95)

Significantly Below Fair Value: 524804 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524804?

Key metric: As 524804 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524804. This is calculated by dividing 524804's market cap by their current earnings.
What is 524804's PE Ratio?
PE Ratio19x
Earnings₹35.82b
Market Cap₹680.64b

Price to Earnings Ratio vs Peers

How does 524804's PE Ratio compare to its peers?

The above table shows the PE ratio for 524804 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.7x
ALKEM Alkem Laboratories
28.5x10.7%₹605.4b
500488 Abbott India
43.2x11.3%₹555.6b
500257 Lupin
36.2x16.5%₹949.8b
ZYDUSLIFE Zydus Lifesciences
22.8x0.4%₹976.3b
524804 Aurobindo Pharma
19x14.2%₹680.6b

Price-To-Earnings vs Peers: 524804 is good value based on its Price-To-Earnings Ratio (19x) compared to the peer average (32.7x).

Price to Earnings Ratio vs Industry

How does 524804's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.8xn/aUS$76.53m
524652 Ind-Swift
1.9xn/aUS$11.93m
No more companies available in this PE range
No. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 524804 is good value based on its Price-To-Earnings Ratio (19x) compared to the Indian Pharmaceuticals industry average (31.2x).

Price to Earnings Ratio vs Fair Ratio

What is 524804's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524804 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19x
Fair PE Ratio37.1x

Price-To-Earnings vs Fair Ratio: 524804 is good value based on its Price-To-Earnings Ratio (19x) compared to the estimated Fair Price-To-Earnings Ratio (37.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 524804 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,171.75
₹1,535.25
+31.0%
10.7%₹1,930.00₹1,225.00n/a28
Jan ’26₹1,351.40
₹1,513.45
+12.0%
13.1%₹1,930.00₹850.00n/a29
Dec ’25₹1,262.40
₹1,513.45
+19.9%
13.1%₹1,930.00₹850.00n/a29
Nov ’25₹1,401.10
₹1,564.68
+11.7%
13.2%₹1,930.00₹850.00n/a28
Oct ’25₹1,438.55
₹1,533.46
+6.6%
14.2%₹1,930.00₹850.00n/a28
Sep ’25₹1,574.95
₹1,524.07
-3.2%
14.6%₹1,930.00₹850.00n/a27
Aug ’25₹1,432.25
₹1,323.96
-7.6%
13.9%₹1,640.00₹850.00n/a27
Jul ’25₹1,212.15
₹1,283.11
+5.9%
13.1%₹1,500.00₹850.00n/a27
Jun ’25₹1,187.00
₹1,275.15
+7.4%
13.3%₹1,500.00₹850.00n/a27
May ’25₹1,152.45
₹1,175.85
+2.0%
12.4%₹1,424.00₹850.00n/a26
Apr ’25₹1,112.65
₹1,159.42
+4.2%
11.5%₹1,400.00₹850.00n/a26
Mar ’25₹1,026.50
₹1,150.26
+12.1%
11.1%₹1,375.00₹850.00n/a27
Feb ’25₹1,070.50
₹1,076.27
+0.5%
14.6%₹1,370.00₹710.00₹1,171.7526
Jan ’25₹1,080.15
₹993.68
-8.0%
13.8%₹1,200.00₹615.00₹1,351.4028
Dec ’24₹1,033.60
₹993.68
-3.9%
13.8%₹1,200.00₹615.00₹1,262.4028
Nov ’24₹858.85
₹867.36
+1.0%
15.3%₹1,055.00₹516.00₹1,401.1028
Oct ’24₹914.20
₹854.50
-6.5%
14.3%₹1,055.00₹600.00₹1,438.5528
Sep ’24₹825.55
₹854.50
+3.5%
14.3%₹1,055.00₹600.00₹1,574.9528
Aug ’24₹818.35
₹681.72
-16.7%
9.2%₹850.00₹554.00₹1,432.2529
Jul ’24₹727.55
₹673.00
-7.5%
9.4%₹850.00₹554.00₹1,212.1528
Jun ’24₹662.60
₹660.14
-0.4%
11.2%₹850.00₹506.00₹1,187.0028
May ’24₹616.45
₹595.54
-3.4%
13.3%₹850.00₹450.00₹1,152.4528
Apr ’24₹518.00
₹578.04
+11.6%
15.0%₹850.00₹430.00₹1,112.6528
Mar ’24₹463.35
₹581.11
+25.4%
15.0%₹850.00₹430.00₹1,026.5028
Feb ’24₹412.55
₹584.56
+41.7%
15.5%₹850.00₹430.00₹1,070.5027
Analyst Price Target
Consensus Narrative from 28 Analysts
₹1.54k
Fair Value
23.7% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 22:29
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurobindo Pharma Limited is covered by 52 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamlesh KotakAsian Markets Securities Private Limited
Meeta ShettyAsian Markets Securities Private Limited
Vijayaraghavan SwaminathanAvendus Spark